Group 3 Pulmonary Hypertension: From Bench to Bedside

被引：40

作者：

Singh, Navneet ^{[1
]}

Dorfmuller, Peter ^{[3
,4
,5
]}

Shlobin, Oksana A. ^{[6
]}

Ventetuolo, Corey E. ^{[1
,2
]}

机构：

[1] Brown Univ, Div Pulm Crit Care & Sleep Med, 593 Eddy St,APC 757, Providence, RI 02903 USA

[2] Brown Univ, Dept Hlth Serv Policy & Practice, Providence, RI USA

[3] Univ Giessen, Dept Pathol, Giessen, Germany

[4] Justus Liebig Univ, Marburg Lung Ctr UGMLC, Giessen, Germany

[5] German Ctr Lung Res DZL, Giessen, Germany

[6] Inova Fairfax Hosp, Adv Lung Dis & Transplant Program, Falls Church, VA USA

来源：

CIRCULATION RESEARCH | 2022年 / 130卷 / 09期

关键词：

hypertension; pulmonary; hypoxia; lung diseases; interstitial; prevalence; ventricular dysfunction; right; INHALED NITRIC-OXIDE; ENDOTHELIAL GROWTH-FACTOR; RIGHT-VENTRICULAR DYSFUNCTION; BRAIN NATRIURETIC PEPTIDE; INTERSTITIAL LUNG-DISEASE; SMOKE-INDUCED EMPHYSEMA; TERM OXYGEN-THERAPY; 6-MINUTE WALK TEST; ANIMAL-MODELS; ARTERIAL-HYPERTENSION;

D O I：

10.1161/CIRCRESAHA.121.319970

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pulmonary hypertension (PH) because of chronic lung disease is categorized as Group 3 PH in the most recent classification system. Prevalence of these diseases is increasing over time, creating a growing need for effective therapeutic options. Recent approval of the first pulmonary arterial hypertension therapy for the treatment of Group 3 PH related to interstitial lung disease represents an encouraging advancement. This review focuses on molecular mechanisms contributing to pulmonary vasculopathy in chronic hypoxia, the pathology and epidemiology of Group 3 PH, the right ventricular dysfunction observed in this population and clinical trial data that inform the use of pulmonary vasodilators in Group 3 PH.

引用

页码：1404 / 1422

页数：19

共 50 条

[31] Parkinson's disease: From bench to bedside
Draoui, A.
El Hiba, O.
Aimrane, A.
El Khiat, A.
Gamrani, H.
REVUE NEUROLOGIQUE, 2020, 176 (7-8) : 543 - 559
[32] Extracranial arteriovenous malformations: from bedside to bench
Qiao, Congzhen
Richter, Gresham T.
Pan, Weijun
Jin, Yunbo
Lin, Xiaoxi
MUTAGENESIS, 2019, 34 (04) : 299 - 306
[33] Right Ventricular Dysfunction in Lupus Patients With Pulmonary Hypertension
Barberato, Silvio Henrique
ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2018, 111 (01) : 82 - 83
[34] Malignant Pleural Mesothelioma: From the Bench to the Bedside
Astoul, P.
Roca, E.
Galateau-Salle, F.
Scherpereel, A.
RESPIRATION, 2012, 83 (06) : 481 - 493
[35] Editorial: Sarcoidosis and autoimmunity: From bench to bedside
d'Alessandro, Miriana
FRONTIERS IN MEDICINE, 2023, 10
[36] Inositol phosphoglycans and preeclampsia: from bench to bedside
Scioscia, Marco
Williams, Philip J.
Gumaa, Khalid
Fratelli, Nicola
Zorzi, Carlotta
Rademacher, Thomas W.
JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2011, 89 (02) : 173 - 177
[37] Bone tissue engineering: from bench to bedside
Woodruff, Maria A.
Lange, Claudia
Reichert, Johannes
Berner, Arne
Chen, Fulen
Fratzl, Peter
Schantz, Jan-Thorsten
Hutmacher, Dietmar W.
MATERIALS TODAY, 2012, 15 (10) : 430 - 435
[38] From Bench to Bedside: Faricimab Enters the Clinic
Boone, Cecilia Villanueva
Wykoff, Charles C.
Fine, Howard F.
OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2022, 53 (06) : 305 - 309
[39] Comorbidities Caused by a Corrupt Cullin 3: Lessons Learned From Bedside to Bench
Wu, Jing
Sigmund, Curt D.
HYPERTENSION, 2022, 79 (01) : 76 - 78
[40] The place of beta-adrenergic receptor blockers in the treatment of arterial hypertension: From bench-to-bedside
Avagimyan, Ashot
Kajaia, Nana
Gabunia, Luiza
Trofimenko, Artem
Sulashvili, Nodar
Sanikidze, Tamar
Gorgaslidze, Nana
Challa, Abhiram
Sheibani, Mohammad
CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (10)

← 1 2 3 4 5 →